Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 18/20 | 1.00 |
| ▸ | CSF1R | P07333 | 17/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 4/20 | 1.00 |
| ▸ | KIT | P10721 | 4/20 | 1.00 |
| ▸ | PDGFRA | P16234 | 4/20 | 1.00 |
| ▸ | RET | P07949 | 1/20 | 0.55 |
| ▸ | RAF1 | P04049 | 2/20 | 0.49 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.49 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.49 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1698589 | 0.97 | FLT3 (0.94) | FLT3CSF1RPDGFRBKITPDGFRA | |
| SCHEMBL29766467 | 0.97 | FLT3 (0.94) | FLT3CSF1RPDGFRBKITPDGFRA | |
| SCHEMBL1698701 | 0.91 | FLT3 (1.00) | FLT3CSF1RPDGFRBKITPDGFRA | |
| SCHEMBL9978760 | 0.91 | FLT3 (0.83) | FLT3CSF1RPDGFRBKITPDGFRA | |
| SCHEMBL1698635 | 0.89 | FLT3 (0.84) | FLT3CSF1RPDGFRBKITPDGFRA | |
| SCHEMBL9978579 | 0.88 | FLT3 (0.79) | FLT3CSF1RPDGFRBKITPDGFRA | |
| SCHEMBL1698796 | 0.88 | FLT3 (0.94) | FLT3CSF1RPDGFRBKITPDGFRA | |
| SCHEMBL20484791 | 0.88 | FLT3 (0.94) | FLT3CSF1RPDGFRBKITPDGFRA | |
| SCHEMBL1698700 | 0.87 | FLT3 (1.00) | FLT3CSF1RPDGFRBKITPDGFRA | |
| SCHEMBL1698608 | 0.87 | FLT3 (0.85) | FLT3CSF1RPDGFRBKITPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250099508-A1 | SYSTEMS, CELL LINES AND METHODS OF PRODUCING AND USING THE SAME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-03-27 | — | — | US | claimed |
| EP-4460314-A2 | SYSTEMS, CELL LINES AND METHODS OF PRODUCING AND USING THE SAME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-11-13 | — | — | EP | claimed |
| US-20240165199-A1 | PROX1 PREVENTS MYXOMATOUS VALVE DISEASE BY INHIBITING PDGF-B SIGNALING | OKLAHOMA MEDICAL RESEARCH FOUNDATION | 2024-05-23 | — | — | US | claimed |
| WO-2023130150-A2 | SYSTEMS, CELL LINES AND METHODS OF PRODUCING AND USING THE SAME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-07-06 | — | — | WO | claimed |
| US-20220412957-A1 | METHODS OF TREATING CANCER PATIENTS WITH RAS NODE OR RTK TARGETED THERAPEUTIC AGENTS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2022-12-29 | — | — | US | claimed |
| EP-4073516-A1 | METHODS OF TREATING CANCER PATIENTS WITH RAS NODE OR RTK TARGETED THERAPEUTIC AGENTS | Celcuity Inc. (US) | 2022-10-19 | — | — | EP | claimed |
| WO-2022182982-A1 | METHODS FOR TREATING C-KIT KINASE MEDIATED DISEASES AND DISORDERS USING A SELECTIVE C-KIT KINASE INHIBITOR | THIRD HARMONIC BIO, INC. (US) | 2022-09-01 | — | — | WO | claimed |
| US-12613236-B2 | Lung fibrosis model and methods of using the same | DUKE UNIVERSITY (US) | 2026-04-28 | — | — | US | disclosed |
| EP-4642465-A1 | A CANCER ASSOCIATED FIBROBLAST (CAF) INHIBITOR FOR USE WITH AN ALTERNATING ELECTRIC FIELD IN A METHOD OF TREATING DISEASES SUCH AS CANCER | Novocure GmbH (CH) | 2025-11-05 | — | — | EP | disclosed |
| WO-2025106862-A1 | METHODS OF TREATING KIT POSITIVE CANCERS WITH A MENIN INHIBITOR | KURA ONCOLOGY, INC. (US) | 2025-05-22 | — | — | WO | disclosed |
| US-12295955-B2 | TTP phosphorylation for the identification of personalized medicines | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2025-05-13 | — | — | US | disclosed |
| US-20250099508-A1 | SYSTEMS, CELL LINES AND METHODS OF PRODUCING AND USING THE SAME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-03-27 | — | — | US | disclosed |
| US-20240390406-A1 | PHOSPHORYLATED TRISTETRAPROLIN AS A BIOMARKER AND THERAPEUTIC TARGET FOR ANTIAGING DRUGS | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2024-11-28 | — | — | US | disclosed |
| WO-2022040606-A1 | COMPOSITIONS AND METHODS TO REDUCE NEUROINFLAMMATION | SEATTLE CHILDREN'S HOSPITAL D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE (US) | 2022-02-24 | — | — | WO | disclosed |
| US-11065243-B2 | Inhibitors of DUX4 induction for regulation of muscle function | SONIC MASTER LIMITED (VG) | 2021-07-20 | — | — | US | disclosed |
| US-20200330452-A1 | Inhibitors of Dux4 Induction for Regulation of Muscle Function | SONIC MASTER LIMITED (VG) | 2020-10-22 | — | — | US | disclosed |
| US-9296722-B2 | Azolyl urea compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2016-03-29 | — | — | US | disclosed |
| US-9296722-B2 | Azolyl urea compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2016-03-29 | — | — | US | disclosed |
| US-20130310357-A1 | Azolyl Urea Compounds and Methods of Use Thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2013-11-21 | — | — | US | disclosed |
| WO-2011150198-A1 | AZOLYL UREA COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2011-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250099508-A1 | SYSTEMS, CELL LINES AND METHODS OF PRODUCING AND USING THE SAME | DCX, SLC10A2, CHAT | FLT3 4815/4885CSF1R 2786/4885PDGFRB 1721/4885 |
| US-20200330452-A1 | Inhibitors of Dux4 Induction for Regulation of Muscle Function | MUSK, MERTK, PRKDC | FLT3 157/4885CSF1R 1809/4885PDGFRB 309/4885 |
| US-11065243-B2 | Inhibitors of DUX4 induction for regulation of muscle function | MUSK, MERTK, PRKDC | FLT3 157/4885CSF1R 1809/4885PDGFRB 309/4885 |
| US-20130310357-A1 | Azolyl Urea Compounds and Methods of Use Thereof | CSF1R, CSF3R, ARG1 | FLT3 4/4885CSF1R 1/4885PDGFRB 733/4885 |
| US-12613236-B2 | Lung fibrosis model and methods of using the same | FN1, ACVR1, DSP | FLT3 406/4885CSF1R 36/4885PDGFRB 493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.